Please find attached press release for Q1FY27 financial results

23rd July, 2026 (1) BSE Ltd (2) National Stock Exchange of India Ltd Listing Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai - 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Symbol: CIPLA (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg Sub: Press Release Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Press Release dated 23rd July, 2026. Kindly take the above information on record. Thanking you, Yours faithfully, For Cipla Limited Rajendra Chopra Company Secretary Encl: As above Prepared by: Simona Dsouza Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380 ` Q1 FY27 Results One India Delivered Highest-ever quarterly Revenue with further Growth Acceleration Income from Operations EBITDA PAT INR 1,192 Cr INR 789 Cr INR 7,119 Cr FY27: (16.7%) (11.1%) Mumbai, July 23, 2026: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its unaudited consolidated financial results for the quarter ended June 30th, 2026. Key Highlights for the Quarter ▪ One-India: The business recorded highest quarterly sales with a solid growth of 12% YoY. Overall Chronic mix improved to 60.4% in the market#. ▪ North America: Delivered quarterly revenue of $ 162 Mn. ▪ One Africa: Prescription business ranked No. 2 in the market*. ▪ Emerging Markets and Europe: Delivered quarterly revenue above $100Mn+, recording a 5% YoY growth in USD terms. ▪ R&D investments: Stood at INR 486 Cr, accounting for 6.8% of sales, up 12.3% YoY, driven by increased product filings and development initiatives. ▪ Strong net cash: Net cash position of INR 9,494 Cr; Debt primarily includes lease liabilities and working capital requirements. #Market data as per IQVIA MAT June’26 *Market data as per IQVIA MAT May’26 “We are pleased to share that we continue to make considerable progress across our focused markets. In Q1FY27, we delivered global revenues of INR 7,119 Cr. Our One-India business grew at solid 12% YoY. Branded Prescription business delivered a robust growth, with key therapies outpacing the market, Trade Generics recorded healthy growth and Anchor brands of Consumer Health Business maintained leadership position. The US business posted a revenue of $ 162 Mn during the quarter. We expect continued sequential growth in North America, supported by upcoming product pipeline. South Africa private business continued to grow faster than the market. Emerging Markets and Europe continued its growth trajectory with revenue growth of 5% YoY in USD terms on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front.” Achin Gupta MD and Global CEO, Cipla Ltd For Queries Contact: Corporate Communications Investor Relatio ns Cipla Ltd. Heena Kanal Diksha Maheshwari Cipla House, CorpComm@cipla.com Investor.Relations@cipla.com Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013 Market Updates ❖ One India Business Branded Prescription: Delivered market# growth of 15.4%, 183 bps higher than IPM. Key therapies like Respiratory, Urology, Cardiac and Anti-diabetes grew at strong double-digit market# growth, with the overall Chronic mix being improved to 60.4%. Trade Generics: The business recorded a healthy growth YoY. The performance was supported by execution excellence in distribution and new introductions. The business launched 3 new products during the quarter. Consumer Health: Anchor brands of Nicotex, Omnigel and Cipladine maintained leadership positions in their respective market segments. ❖ North America Delivered quarterly revenue of $ 162 Mn. Albuterol ranked No. 1 in the overall U.S. Albuterol MDI market, with a 21% market share*. During the quarter, the business launched gVentolin following regulatory approval received last quarter, with commercial shipments commenced and volumes expected to increase gradually as supply ramps up. This was complemented with launch of Nintedanib and Dapagliflozin, expanding our presence in high-growth therapy areas. ❖ One Africa In South Africa Private Market secondary growth was at 6.5% versus the market** growth of 5.7%. The prescription business maintained its No.2 position. ❖ Emerging Markets and Europe Deep market focus strategy in Emerging Markets and Europe has laid a solid foundation, with the business delivering a growth of 5% YoY in USD terms with an uptick in both DTM and B2B categories, along with sustained overall margins. #Market data as per IQVIA, Quarter ended June 2026|*Market data as per IQVIA week ending 26th June’26 |** Market data as per IQVIA MAT May’26 QUARTERLY BUSINESS WISE SALES PERFORMANCE Y-o-Y Business (In INR Cr) Q1FY27 Q1FY26 Growth India (Rx + Gx + CHL^) 3,452 3,070 12% North America 1,532 1,933 -21% One Africa# 977 871 12% South Africa 658 695 -5% Emerging Markets and Europe 999 861 16% API and Others 160 222 -28% Total 7,119 6,957 2% ^ CHL – Cipla Health limited |# Includes South Africa, North Africa, Sub-Saharan Africa and Cipla Global Access CONSOLIDATED PROFIT & LOSS STATEMENT In INR Cr Q1FY27 Q1FY26 Total Income from Operations 7,119 6,957 EBITDA 1,192 1,778 % of Income from Operations 16.7% 25.6% PAT 789 1,298 BALANCE SHEET Key Balance Sheet Items (INR Cr) June-26 June-25 Equity 34,443 32,665 Total Debt# 600 459 Inventory 6,714 6,091 Cash and Cash Equivalents* 10,094 10,838 Trade Receivables 5,948 6,254 Trade Payables 3,446 3,093 Net Tangible Assets 7,889 6,669 Goodwill and Intangibles 6,928 5,138 #Total debt includes lease liabilities and borrowings| * Cash & cash equivalents include current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances Announcement Cipla to release Q1FY27 unaudited Financial Results on July 23, 2026 Date: July 23, 2026 • 1600 hrs IST – EARNINGS CONFERENCE CALL The Company will host an earnings conference call at 1600 hrs IST (1830 hrs SST/HKT, 1030 hrs GMT, 0530 hrs US ET), during which the leadership team will discuss financial performance and take questions. A transcript of the conference call will be available at www.cipla.com. Earnings Conference Call Dial-in Information Date and Time July 23, 2026 at 1600 – 1700 hrs IST 1830 – 1930 hrs SST/HKT 1030 – 1130 hrs GMT 0530 – 0630 hrs US ET Dial-in Numbers Universal Access Primary Access: (+91 22 6280 1562) (+91 22 7115 8387) Diamond pass link Click here to register Toll Free Number USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045 ABOUT CIPLA LTD Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT June’26), 2nd Largest in the pharma prescription market in South Africa (IQVIA MAT May’26), and 2nd largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT June’26). For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bring [Showing first 8,000 characters — download PDF for full document]